UBS’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

UBS’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-1,178	Closed	-$23K	–	10981
2014 Q1	$23K	Buy	1,178 +717	+156%	+$12.2K	﹤0.01%	7921
2013 Q4	$8K	Buy	+461	New	+$5.73K	﹤0.01%	9220

Other funds holding FPRX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

UBS's FPRX Position: Q2 2014 in Review

UBS sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2014, closing a stake of 1,178 shares — an estimated $23K sold.

UBS first reported a position in FPRX in Q4 2013 and held it in 2 quarters. The position peaked at $23K in Q1 2014. 62 funds tracked by Wall St. Rank hold FPRX as of Q2 2014.

UBS reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2014 after selling out during the quarter.
UBS sold 1,178 Five Prime Therapeutics, Inc. shares in Q2 2014, an estimated $23K.
UBS first reported a position in Five Prime Therapeutics, Inc. in Q4 2013 and held it in 2 quarters.
UBS's Five Prime Therapeutics, Inc. position peaked at $23K in Q1 2014.
62 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2014.

Based on UBS's 13F filing for Q2 2014, filed 14 Aug 2014.